Personal profile
Public Profile
David Yeung is a postdoctoral research fellow with the Precision Medicine Theme at the SAHMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases. David also has project with Prof Deb White of the Cancer Theme, who heads the national effort in understanding and improving outcomes in high risk ALL. He has co-authored 24 publications in peer reviewed journals and 2 book chapters in postgraduate text books.
Collaborations and top research areas from the last five years
-
Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients
Omar, M. M. A., Alanazi, M. A., Yeung, D. T., Hughes, T. P. & Jackson, D. E., Apr 2026, In: International Journal of Molecular Sciences. 27, 8, 3623.Research output: Contribution to journal › Article › peer-review
Open Access -
Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study
the Australasian Leukaemia and Lymphoma Group, Jan 2026, In: HemaSphere. 10, 1, e70291.Research output: Contribution to journal › Article › peer-review
Open Access -
Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study
Cibich, A., Wechalekar, G., Shanmuganathan, N., Singhal, D., Beligaswatte, A., Wayte, R., Selby, P., Branford, S., Yeung, D., Bardy, P. & Hiwase, D., 2026, (Accepted/In press) In: Transplantation and Cellular Therapy.Research output: Contribution to journal › Article › peer-review
Open Access -
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
the Australasian Leukaemia and Lymphoma Group, Feb 2026, In: British Journal of Haematology. 208, 2, p. 599-607 9 p.Research output: Contribution to journal › Article › peer-review
-
Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia
Kim, D. D. H., Zackova, D., Breccia, M., Lang, F., Sakaida, E., Jiang, Q., De Paz, R., Liu, B., Isfort, S., Yeung, D., Takaku, T. & Brümmendorf, T. H., Jan 2026, (Accepted/In press) In: Blood Reviews. 76, 101366.Research output: Contribution to journal › Review article › peer-review
Open Access
Prizes
Activities
-
Ph+ ALL Management - 2024
Yeung, D. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
When Frontline Therapy Fails
Yeung, D. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
CML Opinion Leaders Training COLT 2024
Yeung, D. (Organiser) & Hughes, T. (Organiser)
17 Oct 2024 → 18 Oct 2024Activity: Participating in or organising an event › Organising a workshop, seminar, course